Free shipping on all orders over $ 500

CYT387

Cat. No. M1700
CYT387 Structure
Synonym:

CYT 11387

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mg USD 100 In stock
50mg USD 280 In stock
200mg USD 700 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
Biological Activity

CYT387 is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. CYT387 inhibits growth of Ba/F3-JAK2V617F and human erythroleukemia (HEL) cells (IC (50) approximately 1500 nM) or Ba/F3-MPLW515L cells (IC (50)=200 nM), but has considerably less activity against BCR-ABL harboring K562 cells (IC50=58000 nM).

Customer Product Validations & Biological Datas
Source Pharmacol Res (2013). Figure 3. CYT387
Method orally
Cell Lines Mice
Concentrations 10 mg/kg
Incubation Time 24 h
Results Neither absence of Mdr1a/1bnor of Bcrp1 showed a significant effect on the overall plasma expo-sure between 0 and 8 h.
Source Pharmacol Res (2013). Figure 2. CYT387
Method Transport assays
Cell Lines MDCK-II cells
Concentrations 5 μM
Incubation Time 2,4 and 8 h
Results In the MDCKII parental cell line, there was a mod-est apically directed transport of CYT387 (transport ratio r = 1.2),which was abrogated with the MDR1-specific inhibitor zosuquidar(Fig. 2A and B), suggesting that this background transport wasmediated by endogenous canine MDR1 present in the MDCKII cells.
Protocol
Cell Experiment
Cell lines Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3–MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells
Preparation method Cell-based assays. Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3–MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells were generously provided by D Gary Gilliland (Brigham and Women’s Hospital, Boston, MA, USA). The TEL/JAK2 and TEL/ JAK3 fusions were generated and introduced into Ba/F3 murine cells as described earlier. The TEL/JAK2- or TEL/JAK3-transfected cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS). Ba/F3 wild-type cells were cultured in RPMI containing 10% FCS supplemented with 5 ng/ml murine IL-3 (Peprotech, Rocky Hill, NJ, USA). Proliferation was measured using the Alamar Blue assay (TREK Diagnostic Systems, Cleveland, OH, USA) after incubating for 72 h at 37℃with 5% CO2.
Concentrations 0~100μM
Incubation time 72 h
Animal Experiment
Animal models murine model of JAK2V617F-dependent MPN
Formulation dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone, Chromasolv Plus; Sigma-Aldrich). Subsequently, the CYT387/NMP mix was diluted with 0.14M Captisol (Cydex Pharmaceuticals Inc) to a concentration of 6 mg/mL and further diluted with 0.1M Captisol to a final concentration of 4 mg/mL.
Dosages 25, 50mg/kg twice daily from day 34 to day 82
Administration oral gavage
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Chemical Information
Molecular Weight 414.46
Formula C23H22N6O2
CAS Number 1056634-68-4
Purity 98.83%
Solubility DMSO
Storage at -20°C
References

Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Sparidans et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 May 1;895-896:174-7. PMID: 22476054.

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan et al. Leukemia. 2011 Dec;25(12):1891-9. PMID: 21788946.

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner et al. Blood. 2010 Jun 24;115(25):5232-40. PMID: 20385788.

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani et al. Leukemia. 2009 Aug;23(8):1441-5. PMID: 19295546.

Related JAK Products
SAR-20347

SAR-20347 is a potent dual inhibitor of JAK1 and TYK2 with IC50 values of 23 and 0.6 nM, respectively.

Itacitinib

Itacitinib, also known as INCB39110 or INCB039110, is a potent JAK1 tyrosine kinase inhibitor.

Solcitinib

Solcitinib is a selective Janus kinase 1 (JAK1) inhibitor, for the treatment of psoriasis, lupus, and ulcerative colitis. Targer: JAK1

PF-06651600

PF-06651600 is a potent and irreversible JAK3-selective inhibitor with an IC50 of 33.1 nM but without activity (IC50 > 10 000 nM) against JAK1, JAK2, and TYK2.

Upadacitinib

Upadacitinib (ABT-494) is a potent and selective Janus kinase (JAK) 1 inhibitor being developed for the treatment of several autoimmune disorders with an IC50 of 43 nM.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: CYT387, CYT 11387 supplier, JAK, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.